Danaher's 3% Core Print Hid a Mid-Teens Bioprocessing Order Book — and CDMO Capex Is Funding the Tools Cycle

Danaher's headline number is a testing business, not a verdict on bioprocessing. Respiratory testing contributed roughly $350 million of revenue in the quarter against a materially larger prior-year base; excluding it, core revenue grew 5.5% and the Biotechnology segment grew 5.0%, with bioprocessing at the upper end of mid-single digits. Core growth excluding respiratory ran 250 basis points hotter than the 3.0% headline, and none of that gap is instrument demand.

Two things are true at once, and the headline captures neither. The reported 8.5% revenue growth is mostly bought: Danaher closed its $9.8 billion cash purchase of Masimo on June 10, 2026, and Diagnostics' 17.0% reported growth against 0.5% core growth implies roughly seven points of group growth from the deal and currency together. And the organic mix is narrow rather than weak — inside Biotechnology, bioprocessing grew at the upper end of mid-single digits while Discovery and Medical fell low single digits. Bioprocessing is the only part of Danaher's life-science portfolio compounding in the mid single digits, while discovery tools are shrinking.

Management was explicit about why revenue understates demand. Bioprocessing revenue grew toward the upper end of mid-single digits, consumables were up mid-single digits led by upstream consumables, and equipment rose only low single digits — while bioprocessing orders grew mid-teens, led by upstream consumables and resins. An order book compounding in the mid-teens against low-single-digit equipment revenue is a conversion schedule, not a demand failure.

Read together, these disclosures describe a supplier paid on someone else's capital decision, taken years before that capital is spent. The tools cycle is real in orders and early in revenue, which is the configuration in which revenue estimates go wrong in both directions: too low for 2027, too high for what the CDMOs can absorb in 2029.

Tools orders are paid for by CDMO capital budgets, so the question is who is spending. The answer is a wave: Samsung Biologics raised KRW 3 trillion in August to fund PolyPeptide and new capacity, PolyPeptide is running capital expenditure at 17.5% of revenue while revenue grows 41.6%, WuXi Biologics is building a fill-finish plant and a 120,000-liter modular site, and Bachem is spending CHF 350-400 million in 2026 with more than CHF 500 million committed to Sisslerfeld. Every one of those commitments is a future order for filters, resins and hardware.

Samsung Biologics is the cleanest illustration of the distinction. It ran Plants 1 through 4 at full utilization in the third quarter, converted KRW 1,490.3 billion of revenue into a 43.0% operating margin, and carries more than USD 21.9 billion of cumulative contract orders. Full utilization is why it can raise KRW 3 trillion at a discount and why its equity trades at 22.6x trailing EV/EBITDA. Scarcity is what the multiple pays for; the capacity wave is what erodes it, and that erosion is a 2029-2032 problem rather than a 2027 one.

The most common error in this theme is to treat GLP-1 peptides and cell-culture biologics as one demand pool. They are not: peptides are made by solid-phase chemistry, antibodies and proteins are grown in bioreactors. PolyPeptide's metabolic therapeutics revenue grew 72.7% in the first half and now makes up 68.4% of its top line — growth that touches no chromatography resin and no bioreactor.

The read is uncomfortable for the CDMO bull case and reassuring for the tools. On enterprise value to sales the market pays twice as much for a dollar of Samsung Biologics' revenue as for a dollar of Danaher's, yet on enterprise value to EBITDA the two sit within about one point of each other — because Samsung converts 43 cents of every sales dollar into operating profit and Danaher converts 20. The entire valuation gap between the CDMO and its supplier is margin, and margin is what a full-utilization plant earns and a new plant does not.

And the tools have already been paid for. Thermo Fisher's market value rose 44% between the end of March and Oct 21, 2026, and Repligen's rose 49% since the end of June, both while their own growth rates stayed in the low-to-mid teens. Danaher closed at $230.33, 43% above its 52-week low of $160.93 and within 5% of its 52-week high of $242.80. The tools cycle is in the price before it is in the revenue, which flips the question from whether a cycle exists to whether the order book converts without a CDMO capex pause.